Jerusalem, Israel: The administration of plant-derived cannabidiol (CBD) extracts provide greater efficacy in the treatment of pain and inflammation than does the use of a purified CBD alternative, according to preclinical data published online ahead of print in the journal Pharmacology & Pharmacy.
Investigators at the Hebrew University, Institute for Drug Research assessed the anti-inflammatory and anti-nociceptive activities of plant-derived CBD extracts in animals. Researchers reported that extracts derived from a CBD-dominant strain of cannabis provided a wider therapeutic window than did the administration of a purified form of CBD provided by a German pharmaceutical company. Authors concluded that the administration of plant-derived extracts is "superior" to the use of synthetic CBD in the treatment of certain inflammatory diseases.
"Our findings [show] that CBD in the presence of other plant constituents improve the dose-response," authors reported. "The higher efficiency of plant extract might be explained by additive or synergistic interactions between CBD and minor phytocannabinoids or non-cannabinoids presented in the extracts."
They concluded: "A lot of research has been made to isolate and characterize isolated single constituents of traditional herbal medicine to find their rationale for therapeutic uses. However, our data together with those of others provide (legitimacy) to introduce a new generation of phytopharmaceuticals to treat diseases that have hitherto been treated using synthetic drugs alone."
For more information, please contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, "Overcoming the bell-shaped dose-response of cannabidiol using cannabis extract enriched in cannabidiol," appears online at: http://www.scirp.org/Journal/PaperInformation.aspx?PaperID=53912#.VRnYTGaACxV.